No quarterly revenue total was found in KALA BIO, INC.'s SEC filings.
Kala Bio, Inc. (KALA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-1.58M
+85.8% vs year-ago quarter
Operating cash flow
$-1.53M
+90.7% vs year-ago quarter
Free cash flow
—
EPS
$-21.32
+75.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
19.34M
+175.5% vs year-ago quarter
Net cash
$-8.85M
Q3 FY2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KALA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Arlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1479419
- Former names
- KALA BIO, Inc. (until Nov 3, 2026); Kala Pharmaceuticals, Inc. (until Jun 23, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.7M | -$1.8M | -$10.2M | -$7.2M | -$11.0M |
| Net income | -$1.6M | -$1.6M | $686,000 | -$7.6M | -$11.2M |
| Diluted EPS | -$21.32 | -$0.14 | $0.05 | -$1.07 | -$85.64 |
| Operating cash flow | -$1.5M | -$2.9M | -$4.6M | -$10.9M | -$16.6M |
| Total assets | $10.6M | $12.3M | $9.5M | $25.0M | $36.1M |
| Total liabilities | $1.5M | $1.6M | $2.5M | $33.7M | $39.3M |
| Stockholders' equity | $9.0M | $10.8M | $7.0M | -$8.7M | -$3.2M |
| Cash and investments | $7.2M | $8.8M | $7.6M | $21.1M | $31.9M |
| Total debt | — | — | — | $29.9M | $29.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 10, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 28, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 23, 2026 | Jul 22, 2026 |
All 675 Kala Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.